For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

CJC-1295 / Ipamorelin Stack vs IGF-1 LR3

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 / Ipamorelin StackIGF-1 LR3
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asCJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combinationInsulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent)
EvidenceFDA-approvedResearch-stage
Dosing range100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol)
AdministrationSubcutaneous injection (both compounds), Administered together in the same injectionSubcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols)
Key side effectsWater retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)Hypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint pain
Cited sources2 references3 references

Key differences

  • Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while IGF-1 LR3 is research-stage.
  • Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols).
  • Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); IGF-1 LR3 is Once daily post-workout, on training days only (common protocol).
  • Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 3 for IGF-1 LR3.

How each works

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

IGF-1 LR3

In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.

Read the full CJC-1295 / Ipamorelin Stack profileRead the full IGF-1 LR3 profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.